Charlotte Harrison

I’m an experienced science writer who focuses on drug discovery, biotechnology and pharmacology.

I’ve worked with Nature Biotechnology, Nature Medicine, Nature Reviews Drug Discovery, Nature Outlook, Nature Briefing: Translational Research, Cure, Lab Animal, Drug Hunter, Frontline Genomics, the Bracken Group, the Eureka Institute, Nature Research Editing Services, BioEdit and individual researchers.

Please excuse the mess below!

Examples of my writing include:

Nature Medicine: Taming the inflammed heart

Nature Outlook: Six key developments in the fight against antimicrobial resistance

Nature Biotechnology: FDA approves pioneering breast cancer drug that nips resistance in the blood | Newcomer anti-IL-33 makes strides in COPD | Can amylin-based drugs upstage GLP-1 agonists? | Biopharma dives into tutor-seeking radioactive drugs | Vertex’s opioid-free drug for acute pain wins FDA approval | CRISPR Nobelists surrender their own European patents |
TCR cell therapies vanquish solid tumors — finally |
CAR-T cells sweep into autoimmunity | Hair loss treatments target the immune system | First gene therapy for β-thalassemia approved | Monkeypox response relies on three vaccine suppliers | Innovators hit by ruling in dispute over cholesterol antibody patent | Coronavirus puts drug repurposing on the fast track |
Drug researchers pursue new lines of attack against COVID-19 |
Focus shifts to antibody cocktails for COVID-19 cytokine storm |

Cure: 10 companies making major advances in autoimmune disease | 10 CRISPR companies to watch in 2026

Lab Animal: New approach methodologies gain momentum, providing human-relevant alternatives to animal models |
Mice on the move| Shared science’s time to shine | 3R centers tap into the human mindset to bolster replacement, reduction and refinement uptake|

Frontline Genomics: This cell will self-destruct in 5 days

A resource for students aged 16–18 years: How enzymes turn biology into technology

Science: My mix-and-match career

Drug Hunter: Why did Bristol Myers Squibb pay $4.1bn for Turning Point Therapeutics?|

I also write:
News briefs | Research highlights | Case studies | Newsletters | Q&As

I hold a PhD in pharmacology from the University of Leicester and have completed postdoctoral positions at the University of Michigan and Pfizer. I worked as an in-house editor at Springer Nature before going freelance. I’m a member of the British Association of Science Writers. I live in Canterbury, a small city with a big cathedral in the south-east corner of the UK.